Effect of empirical treatment on outcomes of clinical trials of diagnostic assays for tuberculosis

The Lancet Infectious Diseases

Volumn 15, Issue 1, 2015, Pages 16-17

  Menzies, Nicolas A ^a   Cohen, Ted ^b   Murray, Megan ^a   Salomon, Joshua A ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC PROCEDURE; HEALTH CARE POLICY; HUMAN; LETTER; MORTALITY; PREDICTIVE VALUE; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY AND SPECIFICITY; SMEAR; TREATMENT OUTCOME; TUBERCULOSIS; XPERT MTB RIF ASSAY; ISOLATION AND PURIFICATION; MYCOBACTERIUM TUBERCULOSIS; REAL TIME POLYMERASE CHAIN REACTION; STANDARDS;

TUBERCULOSTATIC AGENT;

ANTITUBERCULAR AGENTS; HUMANS; MYCOBACTERIUM TUBERCULOSIS; REAL-TIME POLYMERASE CHAIN REACTION; TUBERCULOSIS;

EID: 84917708496     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(14)71026-6     Document Type: Letter

References (5)

1. Menzies NA, Cohen T, Lin H-H, Murray M, Salomon JA Population health impact and cost-effectiveness of tuberculosis diagnosis with Xpert MTB/RIF: a dynamic simulation and economic evaluation. PLoS Med 2012, 9:e1001347.
2. Vassall A, van Kampen S, Sohn H, et al. Rapid diagnosis of tuberculosis with the Xpert MTB/RIF assay in high burden countries: a cost-effectiveness analysis. PLoS Med 2011, 8:e1001120.
3. Theron G, Zijenah L, Chanda D, et al. Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial. Lancet 2014, 383:424-435.
4. Churchyard G, McCarthy K, Fielding KL, et al. Effect of Xpert MTB/RIF on early mortality in adults with suspected TB: a pragmatic randomized trial. 21st Conference on Retroviruses and Opportunistic Infections; Boston, MA, USA. March 3-6, 2014. Oral Abstract 95.
5. Theron G, Peter J, Dowdy D, Langley I, Squire SB, Dheda K Do high rates of empirical treatment undermine the potential effect of new diagnostic tests for tuberculosis in high-burden settings?. Lancet Infect Dis 2014, 14:527-532.